Innate Pharma S.A. (IPHA)
NASDAQ: IPHA · Real-Time Price · USD
1.695
-0.005 (-0.29%)
At close: Sep 25, 2026, 4:00 PM EDT
1.700
+0.005 (0.29%)
After-hours: Sep 25, 2026, 4:10 PM EDT
Innate Pharma Market Cap
Innate Pharma has a market cap or net worth of $153.98 million as of September 25, 2026. Its market cap has decreased by -12.30% in one year.
Market Cap
153.98M
Enterprise Value
164.59M
1-Year Change
-12.30%
Ranking
Category
Stock Price
$1.70
ChartMarket Cap Chart
Since October 18, 2019, Innate Pharma's market cap has decreased from $480.08M to $153.98M, a decrease of -67.93%. That is a compound annual growth rate of -15.11%.
| Date | Market Cap | % Change |
|---|---|---|
| Sep 25, 2026 | 153.98M | -11.19% |
| Dec 31, 2025 | 173.38M | 4.71% |
| Dec 31, 2024 | 165.58M | -29.08% |
| Dec 29, 2023 | 233.49M | -17.19% |
| Dec 30, 2022 | 281.97M | -29.50% |
| Dec 31, 2021 | 399.94M | 19.60% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro |
| Oct 18, 2019 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Related Stocks
| Company | Market Cap |
|---|---|
| NovaBridge Biosciences | 168.20M |
| Tonix Pharmaceuticals Holding | 166.36M |
| Minerva Neurosciences | 164.73M |
| Acumen Pharmaceuticals | 161.63M |
| Outlook Therapeutics | 159.65M |
| Jyong Biotech | 159.60M |
| Humacyte | 157.98M |
| Molecular Partners AG | 157.07M |